Berthold Behl

USPTO Granted Patents = 40 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 183(Granted Patents)

Location History:

Limburgerhof, DE (1996 - 2002)
Wiesbaden, DE (2014 - 2017)
Ludwigshafen, DE (1994 - 2018)

Company Filing History:

22 out of 167

Abbvie Deutschland Gmbh and Co Kg

Basf Aktiengesellschaft

patents

4. 7 out of 4,179

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 1994-2018

Loading Chart...

Areas of Expertise:

Phosphodiesterase Inhibitors

Oxindole Derivatives

Benzazepine Compounds

Isoquinoline Inhibitors

Phenalkylamine Derivatives

Aminoindane Compounds

Tetrahydroisoquinolines

Heterocyclic Compounds

Quinoxalinediones

Neuroleptics

Triazolopyrimidones

Central Nervous Disorders

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9938269 - Inhibitor compounds of phosphodiesterase type 10A (2018-04-10),

2. 9657034 - Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors (2017-05-23),

3. 9657002 - Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseases (2017-05-23),

4. 9475808 - Inhibitor compounds of phosphodiesterase type 10A (2016-10-25),

5. 9309200 - Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy (2016-04-12),

6. 9273068 - Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A (2016-03-01),

7. 9273036 - Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases (2016-03-01),

8. 9238619 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy (2016-01-19),

9. 9227930 - Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy (2016-01-05),

10. 9163019 - Inhibitor compounds of phosphodiesterase type 10A (2015-10-20),

11. 9138494 - Radiolabeled PDE10A ligands (2015-09-22),

12. 9096619 - Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy (2015-08-04),

13. 9067871 - Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy (2015-06-30),

14. 9051280 - Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy (2015-06-09),

15. 9045459 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy (2015-06-02),

Title: Berthold Behl: Innovator in Therapeutic Compounds

Introduction: Berthold Behl is a notable inventor based in Ludwigshafen, Germany, known for his significant contributions to the pharmaceutical field. With a remarkable portfolio of 40 patents, he has focused on developing innovative compounds aimed at treating various medical disorders.

Latest Patents: Among his recent inventions are novel carboxamide compounds that act as inhibitor compounds of phosphodiesterase type 10A. These compounds are part of pharmaceutical compositions designed for therapeutic use in managing neurological and psychiatric disorders. His work emphasizes not only the treatment of symptoms but also reducing the risk of such disorders.

Additionally, Berthold has developed oxindole derivatives that carry an oxetane substituent. These innovative compounds are crucial for treating vasopressin-related diseases, marking a significant advancement in therapeutic options for such conditions.

Career Highlights: Throughout his career, Berthold Behl has made impactful contributions while working with prominent companies such as AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His focus on drug development and therapeutic innovations has established him as a leader in the field.

Collaborations: Berthold has worked alongside esteemed colleagues like Michael Ochse and Wilhelm Amberg, combining their expertise to push the boundaries of medical research and drug development.

Conclusion: Berthold Behl’s dedication to innovation in therapeutic compounds has led to significant advancements in the treatment of complex medical disorders. His extensive portfolio of patents underscores his role as a pioneering inventor in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.